Please login to the form below

Not currently logged in
Email:
Password:

ASP015K

This page shows the latest ASP015K news and features for those working in and with pharma, biotech and healthcare.

Janssen adds Astellas JAK inhibitor to its immunology portfolio

Janssen adds Astellas JAK inhibitor to its immunology portfolio. Licenses oral rheumatoid arthritis and psoriasis candidate ASP015K. ... But the agreement only covers ASP015K as an oral treatment for immune-mediated inflammatory diseases.

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Company acquisition. 3, 500. Astellas/ J&J. ASP015K, an oral JAK inhibitor for RA (p3).

  • Pharma deals during October 2012 Pharma deals during October 2012

    Heading the deal table is the $945m licence between Astellas Pharma and Janssen for the exclusive rights outside Japan to ASP015K, an oral janus kinase (JAK) inhibitor that is undergoing phase ... Astellas / Janssen. Licence. ASP015K for RA, psoriasis

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics